In a major breakthrough for its international expansion, Taixing's biopharmaceutical sector has achieved a significant milestone. Space Peptides Pharmaceutical (Taizhou) recently secured Drug Master File (DMF) filing with the U.S. Food and Drug Administration, or FDA, for its semaglutide active pharmaceutical ingredient (API), granting the company a key passport into mainstream global healthcare markets.
Located in the Taixing Economic Development Zone since 2019 with an investment exceeding 1 billion yuan ($149.34 million), Space Peptides specializes in peptide drug R&D and manufacturing. The FDA recognition validates the firm's technical rigor and standardized production, setting the stage for a steady expansion of global orders through 2026.
This success reflects Taixing's broader strategy to build a comprehensive "R&D + API + finished drugs" industry chain. To support high-end biopharma and chemical API projects, the zone is currently constructing 10 standardized industrial facilities providing end-to-end operational support.
Through targeted investment, Taixing has attracted industry giants including WuXi AppTec, BrightGene, and Sinochem Kangyuan. Moving forward, the city will expedite project approvals and construction for key investments, further enhancing its industrial ecosystem and driving high-quality growth.